Clinical trials located in

Macerata

Macerata city is located in Italy. Currently, 7 clinical trials are being conducted in this city.

Macerata, nestled in Italy’s Marche region, is renowned for its rich history and cultural heritage. This hilltop city, established in the 10th century, is encircled by ancient walls offering panoramic views of the surrounding countryside. Macerata houses the Sferisterio, a unique open-air opera venue with exceptional acoustics, dating back to the 1820s. The city is also home to one of Italy’s oldest universities, founded in 1290, contributing to its vibrant academic atmosphere. Notably, Macerata’s historical center is adorned with Renaissance architecture, including the Palazzo dei Diamanti and the Basilica della Misericordia, showcasing the city’s artistic and architectural prowess.

  • CT-EU-00024507

    Study of new drug ARV-471 (PF-07850327) and fulvestrant in patients with advanced breast cancer

    The study looks at advanced breast cancer that has spread to other parts of the body (metastasizes). It is aimed at patients with ER+/HER2- breast cancer, which means that the cancer responds to estrogen (a hormone) and does not have excessive amounts of the HER2 protein. The study will compare two drugs: ARV-471 (PF-07850327, vepdegestrant) and fulvestrant.

    Fulvestrant is a drug already used to treat breast cancer, while ARV-471 is a new drug. The aim of this study is to determine whether ARV-471 is safe and effective compared to fulvestrant in patients with advanced breast cancer that cannot be cured by surgery or radiotherapy.

    The study is open to adults with breast cancer recurrence or metastases that cannot be fully cured by surgery or radiotherapy. Candidates should have a confirmed diagnosis of ER+/HER2- breast cancer and previous treatment with CDK4/6 inhibitors combined with hormonal therapy. Patients must not have active brain metastases or liver, kidney or bone marrow failure.

    Treatment continues until the cancer gets worse or the side effects become too severe. Clinic meetings take place approximately every 4 weeks.

    • Vepdegrestrant/ARV-471
    • Fulvestrant
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Breast cancer study: evaluating pre- and post-surgery treatment with Dato-DXd, durvalumab, and pembrolizumab

    The study focuses on triple-negative breast cancer (TNBC) or low hormone receptor and HER2-negative breast cancer. The effectiveness and safety of two different therapies will be evaluated.

    The experimental therapy includes Datopotamab Deruxtecan (Dato-DXd) and Durvalumab, both before surgery (neoadjuvant) and after surgery (adjuvant). In cases of remaining disease, patients may also receive chemotherapy. Patients with BRCA gene mutations may receive Olaparib.

    The comparative therapy involves Pembrolizumab combined with chemotherapy, also before and after surgery. In cases of remaining disease, patients may receive additional chemotherapy and Olaparib.

    The goal is to determine which therapy is more effective and safer in treating TNBC or low hormone receptor and HER2-negative breast cancer.

    The study includes adults with newly diagnosed, untreated breast cancer, confirmed histologically as stage II or III, with appropriate physical fitness. Patients with a history of other cancers, active viral infections, or pregnant or breastfeeding women are excluded.

    • Epirubicin
    • Doxorubicin
    • Dato-DXd
    • Carboplatin
    • Pembrolizumab
    • olaparib
    • Capecitabine
    • Durvalumab
    • Cyclophosphamide
    • Paclitaxel
  • Dato-DXd versus Standard Chemotherapy in Advanced Triple-negative Breast Cancer Study

    This clinical trial investigates a new treatment, Dato-DXd, compared to standard chemotherapy for patients with triple-negative breast cancer that is locally recurrent, inoperable, or metastatic and not suitable for PD-1/PD-L1 inhibitor therapy. The study, open to adults, aims to assess the treatment’s effectiveness and safety through random assignment to either Dato-DXd or investigator-chosen chemotherapy. The trial seeks 600 participants and involves regular monitoring of health and progression of the disease. It emphasizes patient eligibility based on specific health criteria and the nature of their breast cancer.

    • Eribulin mesylate
    • Dato-DXd
    • Carboplatin
    • nab-Paclitaxel
    • Capecitabine
    • Paclitaxel
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Italy:

.